Samik Pharmaceutical Company LTD. (KOSDAQ:014950)
South Korea · Delayed Price · Currency is KRW 7,910.00
-390.00 (-4.70%)
At close: Sep 11, 2026
KOSDAQ:014950 Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Operating Revenue | 62,262 | 60,020 | 55,857 | 51,229 |
Other Revenue | - | -0 | -0 | - |
| 62,262 | 60,020 | 55,857 | 51,229 | |
Revenue Growth | 8.69% | 7.45% | 9.04% | - |
Cost of Revenue | 19,352 | 17,722 | 17,119 | 17,359 |
Gross Profit | 42,910 | 42,298 | 38,738 | 33,870 |
Selling, General & Admin | 38,628 | 36,562 | 32,612 | 28,847 |
Research & Development | 1,979 | 2,060 | 1,943 | 1,757 |
Amortization of Goodwill & Intangibles | 6.41 | 5.08 | 25 | 56.12 |
Other Operating Expenses | 323.33 | 279.95 | 302.34 | 287.89 |
Operating Expenses | 41,087 | 39,025 | 35,060 | 31,073 |
Operating Income | 1,823 | 3,273 | 3,678 | 2,796 |
Interest Expense | -58.44 | -29.22 | -12.26 | -18.53 |
Interest & Investment Income | 525.09 | 301.52 | 186.69 | 198.16 |
Currency Exchange Gain (Loss) | -2.85 | 0.92 | 1.75 | 1.36 |
Other Non Operating Income (Expenses) | -3,910 | -3,893 | 213.21 | 147.23 |
EBT Excluding Unusual Items | -1,623 | -346.44 | 4,067 | 3,124 |
Gain (Loss) on Sale of Investments | 141.79 | 348.99 | 300.14 | 298.32 |
Gain (Loss) on Sale of Assets | 45.47 | 45.98 | 9.5 | 0.07 |
Asset Writedown | - | - | -23.8 | - |
Pretax Income | -1,436 | 48.52 | 4,353 | 3,423 |
Income Tax Expense | 61.8 | 803.41 | 830.99 | 453.53 |
Net Income | -1,498 | -754.89 | 3,522 | 2,969 |
Net Income to Common | -1,498 | -754.89 | 3,522 | 2,969 |
Net Income Growth | - | - | 18.62% | - |
Shares Outstanding (Basic) | 9 | 8 | 7 | 7 |
Shares Outstanding (Diluted) | 9 | 8 | 7 | 7 |
Shares Change | 23.14% | 7.92% | 0.15% | - |
EPS (Basic) | -170.03 | -99.50 | 501.00 | 423.00 |
EPS (Diluted) | -170.03 | -99.50 | 501.00 | 423.00 |
EPS Growth | - | - | 18.44% | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Free Cash Flow | -2,395 | -1,346 | 3,543 | 874.05 |
Free Cash Flow Per Share | -271.95 | -177.44 | 503.91 | 124.52 |
Gross Margin | 68.92% | 70.47% | 69.35% | 66.11% |
Operating Margin | 2.93% | 5.45% | 6.59% | 5.46% |
Profit Margin | -2.40% | -1.26% | 6.31% | 5.80% |
Free Cash Flow Margin | -3.85% | -2.24% | 6.34% | 1.71% |
EBITDA | 3,141 | 4,649 | 5,029 | 4,074 |
EBITDA Margin | 5.04% | 7.75% | 9.00% | 7.95% |
D&A For EBITDA | 1,317 | 1,376 | 1,351 | 1,278 |
EBIT | 1,823 | 3,273 | 3,678 | 2,796 |
EBIT Margin | 2.93% | 5.45% | 6.59% | 5.46% |
Effective Tax Rate | - | 1655.90% | 19.09% | 13.25% |
Advertising Expenses | - | 669.39 | 565.36 | 753.43 |